The biotech firm raised its full-year guidance after Q2 revenue rose 10% year-over-year to exceed $10 billion.
Amgen increased its 2026 revenue outlook to a range of $38.2 billion to $39.4 billion, up from prior guidance, following a strong second quarter. Non-GAAP earnings per share are now projected at $22.30 to $23.50 for the year.
The company reported Q2 revenue above $10 billion, marking a 10% year-over-year increase. Management highlighted double-digit sales growth across 22 products and expressed confidence in expanding patient reach for its medicines and biosimilars in the second half.
The updated guidance comes as Amgen prepares for a transition in its CFO role, though no immediate market reaction was detailed in the earnings call.